Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Прекращено Фаза II Россия

Ronacaleret; Teriparatide; Alendronate

Study CR9108963: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis

Номер протоколаCR9108963
ФазаФаза II
Участников по плану — во всех странах исследования564
Сроки14.05.2007 — 26.12.2008
Начало: 14 мая 2007Окончание: 26 декабря 2008
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00471237/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • Исследование прекращено досрочно, новых участников не набирают.
  • Возраст участников: 18–79 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 564 чел. во всех странах исследования.
  • Плановая дата окончания (12.2008) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–79 лет
ПолТолько женщины
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 53 · невключение: 11

Критерии включения

  • Inclusion:
  • Informed consent: Subject is willing and able to provide written informed consent.
  • Menopausal status: Ambulatory female aged < 80 years at screening and >5 years postmenopausal.
  • T-Score: A subject with either no or only one prevalent vertebral fracture is eligible for inclusion if she satisfies one of the following T-score requirements:
  • If no prevalent vertebral fracture subject must have an absolute BMD value consistent with a T-score of less than or equal to -2.5 and greater than -4.0 at either the femoral neck, total hip, trochanter, or lumbar spine, or If one prevalent vertebral fracture subject must have an absolute BMD value consistent with a T-score of less than or equal to -2.0 and greater than -4.0 at either the femoral neck, total hip, trochanter, or lumbar spine.
  • Suitable vertebra: Two or more vertebra in the range of L1 to L4 that are suitable for BMD measurement by DXA.
  • Protocol compliance: Subject who, in the opinion of the investigator, is willing and able to comply with the requirements of the protocol.
  • Exclusion:
  • T-Score: Has an absolute BMD value consistent with a T-score less than or equal to -4.0 at either the femoral neck, total hip, trochanter, or lumbar spine.
  • Vertebral fractures: Has >1 prevalent vertebral fracture at the screening visit.
  • Non-vertebral fractures: Any previous non-vertebral osteoporosis related/fragility fracture after age 40.
  • Spine deformity: Significant spine deformity which would preclude DXA/QCT assessments.
  • BMI: BMI ≥33kg/m2.
  • Bone metabolic diseases: Other than osteoporosis, history or concurrent diseases affecting bone metabolism (e.g., osteomalacia, hyperparathyroidism, hyperthyroidism).
  • GI disease: History of major upper gastrointestinal disease
  • Malabsorption: Active or history of malabsorption (e.g., history of celiac disease, irritable bowel syndrome or inflammatory bowel disease).
  • Liver disease: Past or current history of liver disease or known hepatic or biliary abnormalities, (with the exception of previously documented diagnosis of Gilbert's syndrome).
  • Rheumatoid arthritis: Active disease or history of rheumatoid arthritis.
  • Nephrolithiasis: History of or active nephrolithiasis (kidney stones).
  • Osteosarcoma risk: Subjects at increased risk of osteosarcoma such as those with Paget's disease of bone or any prior external beam or implant radiation therapy involving the skeleton.
  • Malignancy: Malignant disease diagnosed within the previous 5 years (except resected basal cell cancer).
  • Biological abnormalities: Any clinically relevant biological abnormality found and/or volunteered at screening (other than those related to the disease under investigation) which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study.
  • Surgical and medical conditions: Presence of the following conditions within six months prior to screening: myocardial infarction, coronary bypass surgery, coronary artery angioplasty, unstable angina, cardiac arrhythmia, clinically evident congestive heart failure, or cerebrovascular accident.
  • Glomerular filtration rate: Glomerular filtration rate (GFR) <35 mL/min as calculated by the Modification of Diet in Renal Disease (MDRD) equation as follows: GFR (mL/min/1.73 m2) = 186 x (Serum creatinine mg/dL)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if African American) (conventional units).
  • QT/QTc prolongation: A marked baseline prolongation of QT/QTc interval (e.g., QTc interval ≥450 msec on the Screening ECG).
  • Torsades de Pointes: A history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
  • Liver chemistries: Liver chemistries \[aspartate aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin\] exceeding 2-fold the upper limit of the laboratory-specified reference range, at screening.
  • Abnormal serum calcium: Serum calcium (total or albumin-adjusted) outside the central laboratory reference range at the screening visit.
  • Abnormal PTH: PTH (intact or whole) outside the normal range.
  • Abnormal creatine phosphokinase: Creatine phosphokinase (CPK) outside the normal range.
  • Abnormal alkaline phosphatase: Alkaline phosphatase outside of the normal range.
  • Thyroid hormone replacement: Subjects receiving thyroid hormone replacement therapy must have a TSH level checked. Subjects will be excluded if TSH levels are <0.1 or >10.0mIU/L. However, subjects will not be excluded if TSH is in the range 0.1-4.5 mIU/L. If TSH is >4.5 and ≤10.0mIU/mL, measure T4 and exclude the subject only if the T4 is outside the normal range.
  • Vitamin D deficiency: Vitamin D deficiency (serum 25-hydroxy vitamin D < 20ng/mL, equivalent to 50nmol/L) at screening. Subjects can undergo vitamin D repletion as per local practice and be re-screened once only for vitamin D levels within the 6-week screening period. They will remain excluded if the re-screened value is < 20ng/mL.
  • Previous strontium or IV bisphosphonate: Any previous treatment with strontium ranelate or intravenous bisphosphonate.
  • Oral bisphosphonates: Any previous treatment with an oral bisphosphonate as follows:
  • any treatment within the last six months
  • one month cumulative treatment within the last 12 months
  • three months cumulative treatment within the past two years, or
  • two years cumulative treatment within the past five years.
  • Fluoride: Treatment with fluoride (dose greater than 10mg/day) within the previous 5 years for osteoporosis.
  • Digoxin: Current therapy with digoxin.
  • Bone metabolism drugs: Treatment with other drugs affecting bone metabolism within the last six months prior to screening:
  • Chronic systemic corticosteroid \[e.g., glucocorticoid, mineralocorticoid\] treatment of no more than 2 intra-articular injections within the past year or use of oral, parenteral, or long-term, high-dose inhaled corticosteroids. Treatment with any topical corticosteroid will not exclude the subject from participating.
  • Hormones \[e.g., estrogens/"natural estrogen preparations"(except for nonsystemic vaginal treatment), 19-norprogestins, SERMs such as raloxifene, anabolic steroids/androgens such as dehydroepiandrosterone (DHEA) or its sulfated form (DHEAS), nandrolone, tibolone, active vitamin D analogs/metabolites such as 1,25-dihydroxy vitamin D (calcitriol) or 1alpha-hydroxyvitamin D3 (1-alpha hydroxycholecalciferol), calcitonin\].
  • Calcineurin inhibitors \[e.g., cyclosporine, tacrolimus\] or methotrexate.
  • Previous anabolic agents: Treatment with PTH, PTH analogues or similar anabolic agent for osteoporosis within the last two years.
  • Contraindications: Contraindications to therapy with calcium or vitamin D.
  • Pregnancy: Women who are pregnant are not allowed in this study.
  • Interfering medications: Vitamin A in excess of 10,000 IU per day, heparin, or lithium, or anticonvulsant medications except benzodiazepines.
  • Investigational drug exposure: Administration of any investigational drug within 90 days preceding the first dose of the study drug.
  • Substance abuse: History or current evidence of drug or alcohol abuse within the previous 12 months.
  • Problems swallowing: Inability to swallow a tablet whole.
  • The following

Критерии невключения

  • do not apply to subjects allocated to the open-label teriparatide group:
  • Calcium channel blockers: Current therapy with calcium channel blockers diltiazem and verapamil.
  • Oral Azole Antifungals: Current therapy with any oral azole antifungal.
  • Immunosuppressants: Current therapy with cyclosporine or oral tacrolimus.
  • Ritonavir: Current therapy with ritonavir.
  • Quinidine: Current therapy with quinidine.
  • Macrolide Antibiotics: Subjects anticipated to require chronic use of macrolide antibiotics.
  • Alendronate Contraindications: Contraindications to therapy with alendronate. Additional Exclusion Criteria for Subjects Recruited at QCT Sites
  • Hip surgery: History of hip surgery resulting in a metal implant on either the left or right side that would cause an artefact on a QCT scan.
  • Additional Exclusion Criteria for Teriparatide Subjects
  • Teriparatide contraindications: Contraindications to therapy with teriparatide according to locally approved datasheet.

Источник: ClinicalTrials.gov, NCT00471237 · запись обновлена в реестре 7 ноября 2017.

Дизайн и результаты

ДизайнРандомизированное, тройное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)564
Почему остановлено (как в реестре): Terminated for futility by sponsor after a pre-planned interim review of data
Что измеряют — первичные конечные точки (8), вторичных — 14
  • Percent Change From Baseline in Bone Marrow Density (BMD) at Month 12 Measured by Dual-Energy X-Ray Absorptiometry (DXA) Scans of the Lumbar Spine (L1-L4) — Baseline (Day 0) and 12 Months
  • Number of Participants With Hypercalcemia — Up to Month 12
  • Number of Participants Withdrew Due to Hypercalcemia — Up to Month 12
  • Number of Participant With Laboratory Abnormalities of Potential Clinical Concern at Any Post-baseline Visit — Up to Month 12
  • Number of Participant With Vital Signs of Potential Clinical Concern at Any Post-baseline Visit — Up to 12 Months
  • Number of Participant With Electrocardiogram (ECG) Findings Reported as Adverse Event — Up to 12 months
  • Mean Change From Baseline in Height — Baseline (Day 0), Month 6, 12 and early withdrawal
  • Mean Change From Baseline in Weight — Baseline (Day 0), Month 6, 12 and early withdrawal

Цель исследования

This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00471237 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.